Gotowa bibliografia na temat „Lymphome primitif des séreuses – Thérapeutique”
Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych
Spis treści
Zobacz listy aktualnych artykułów, książek, rozpraw, streszczeń i innych źródeł naukowych na temat „Lymphome primitif des séreuses – Thérapeutique”.
Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.
Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.
Artykuły w czasopismach na temat "Lymphome primitif des séreuses – Thérapeutique"
Gendre, T., C. Giron, S. Evrard, B. Lapergue, P. Graveleau i F. Bourdain. "Lymphome primitif des séreuses méningé révélé par un syndrome HaNDL". Pratique Neurologique - FMC 5, nr 3 (wrzesień 2014): 219–22. http://dx.doi.org/10.1016/j.praneu.2014.06.010.
Pełny tekst źródłaGruffat, Henri, i Evelyne Manet. "Co-infection EBV/KSHV". médecine/sciences 34, nr 1 (styczeń 2018): 79–82. http://dx.doi.org/10.1051/medsci/20183401017.
Pełny tekst źródłaLerisson, M., E. Frouin, R. Benjamin, L. Galicier, V. Costes i O. Dereure. "Détermination cutanée inédite d’un lymphome primitif des séreuses HHV8+ chez un patient VIH+". Annales de Dermatologie et de Vénéréologie 140, nr 12 (grudzień 2013): S486. http://dx.doi.org/10.1016/j.annder.2013.09.283.
Pełny tekst źródłaBoutoille, D., S. Léautez i F. Raffi. "Le lymphome primitif des séreuses: Une forme rare de lymphome associé à l'herpesvirus 8 dans le sida". La Revue de Médecine Interne 20, nr 6 (czerwiec 1999): 544. http://dx.doi.org/10.1016/s0248-8663(99)80096-4.
Pełny tekst źródłaRapp, C., P. Imbert, M. Jagou, E. Oksenhendler i T. Debord. "D-29 Rémission prolongée d'un lymphome primitif des séreuses compliquant une infection à VIH". Médecine et Maladies Infectieuses 34 (czerwiec 2004): S152. http://dx.doi.org/10.1016/s0399-077x(04)90187-4.
Pełny tekst źródłaDimitriu, A. G., I. Miron, C. Jitareanu i T. Condurache. "P18 Hémato - Oncologie Lymphome nonhodgkinien primitif du cœur. Étude clinique et thérapeutique". Archives de Pédiatrie 10 (maj 2003): s283. http://dx.doi.org/10.1016/s0929-693x(03)90532-x.
Pełny tekst źródłaHoang-Xuan, Khê. "Le lymphome cérébral primitif du système nerveux central : un défi diagnostique et thérapeutique". Bulletin de l'Académie Nationale de Médecine 199, nr 8-9 (listopad 2015): 1331. http://dx.doi.org/10.1016/s0001-4079(19)30819-2.
Pełny tekst źródłaFourati, N., S. Kanoun Belajouza, H. Regaieg, A. Khlif i N. Bouaouina. "Lymphome de Hodgkin primitif osseux de la région sacrée : un défi diagnostique et thérapeutique". Cancer/Radiothérapie 21, nr 1 (luty 2017): 51–54. http://dx.doi.org/10.1016/j.canrad.2016.09.013.
Pełny tekst źródłaBenmoussa, Amine, Kawtar Tlohi, Maryam Qachouh, Nisrine Khoubila, Siham Cherkaoui, Mouna Lmchaheb, Mohamed Rachid i Abdellah Madani. "Lymphome B diffus à grandes cellules splénique primitif : une cause rare de splénomégalie isolée". Annales Africaines de Medecine 16, nr 2 (23.05.2023): e5126-e5129. http://dx.doi.org/10.4314/aamed.v16i2.13.
Pełny tekst źródłaDjelo, DIALLO BOUBACAR. "Primitive pleural lymphoma developed on sequelae of pneumothorax therapeutics". Journal of functional ventilation and pulmonology 10, nr 31 (15.06.2019): 50–53. http://dx.doi.org/10.12699/jfvpulm.10.31.2019.50.
Pełny tekst źródłaRozprawy doktorskie na temat "Lymphome primitif des séreuses – Thérapeutique"
Gothland, Adélie. "La Primaquine, une thérapie innovante et ciblée pour les pathologies associées à l’infection par l’Herpèsvirus humain 8". Electronic Thesis or Diss., Sorbonne université, 2021. https://accesdistant.sorbonne-universite.fr/login?url=https://theses-intra.sorbonne-universite.fr/2021SORUS148.pdf.
Pełny tekst źródłaThe Human Herpesvirus 8 (HHV-8) is one of seven recognized human cancer causing viruses. HHV-8 is a principal causative agent of several human cancers including Kaposi’s sarcoma (KS), multicentric Castleman’s disease (MCD) and primary effusion lymphoma (PEL), which represent important and difficult to treat clinical problem, with very few therapeutic options. In the present in vitro study, we demonstrated the specific cytotoxic and pro-apoptotic effect of the antimalarial primaquine disphosphate in HHV-8-infected PEL cells, without any toxicity on different uninfected cells. We also found that primaquine-induced oxidative stress and pro-apoptotic UPR activated by excessive reticulum endoplasmic stress, to be part of the pro-apoptotic mechanisms of action of primaquine in PEL cells. Finally, PQ treatment had a clinical positive effect on tumor growth in a in vivo NOD/SCID xenograft PEL mouse model, as well as in a pilot clinical study in human harboring very severe KS. Importantly, primaquine was well tolerated and none adverse event and overt toxic effects were observed in both primaquine-treated mice and patients. The combination of preclinical and clinical observations and results from our analysis thereby raising the possibility that primaquine may be used as a promising targeted agent in treatment of HHV-8-associated cancers
Boulanger, Emmanuelle. "Lymphomagenèse associée à l'Herpèsvirus Humain-8 : des épisomes aux épitopes". Paris 5, 2006. http://www.theses.fr/2006PA05D032.
Pełny tekst źródłaPrimary effusion lymphoma (PEL) tumor cells are latently infected with human herpesvirus-8 (HHV-8) and co-infected in most cases, with Epstein-Barr virus (EBV). HHV-8 and EBV genomes persist in the nucleus as covalently closed episomes. 1. Molecular analyses of lymphoid and episome clonalities showed monoclonal IgH gene rearrangements in all PEL tumors analysed (n=15), and a monoclonal pattern of EBV episomes in all EBV-positive cases (n=10). However, five cases were found to be monoclonally infected with HHV-8 whereas ten cases contained a biclonal or oligoclonal pattern of HHV-8 episomes. 2. Two epitopes from the HHV-8 latency-associated nuclear antigen-1 (LANA-1) protein were able to blind HLA-B*0702 molecules with a strong affinity, and induced specific cytotoxic T-cell responses (CTL) into HLA-B*0702 transgenic mice. However, these peptides failed to be naturally processed from the endogenous protein, suggesting the existence of immune escape mechanisms
Jary, Aude. "Déterminants moléculaires et cliniques de l’infection par l’herpèsvirus humain 8 : facteurs impliqués dans la transmission du HHV-8 et le développement des maladies associées". Electronic Thesis or Diss., Sorbonne université, 2020. http://www.theses.fr/2020SORUS332.
Pełny tekst źródłaThe human herpesvirus 8 is an oncogenic virus involved in the development of all forms of Kaposi’s sarcoma (KS), but also in certain forms of multicentric Castleman disease (MCD) and in primary effusion lymphoma (PEL). The aim of this work was to study the clinical and virological determinants in HHV-8 infection and associated with its three main diseases. Thus, in the study 1, the HHV-8 DNA viral load associated with KS was lower compared with that found in hemopathies, probably due to the pathophysiology of each disease, but other factors could also be involved. Indeed, in the study 2, the HHV-8 subtype influenced the viral load and the severity of the clinical presentation of KS. In addition, we have identified a new variant associated with severe clinical forms, reinforcing the postulate of virological determinants involved in the pathophysiology of the different diseases. Despite the era of antiretrovirals, immunity would still play an important role because in the study 1, the CD4 count was low and inversely correlated with the HHV-8 viral load in KS and MCD whereas in study 3, epidemic KSs with a sustained immunological and virological response for HIV infection were associated with a CD4 / CD8 ratio of less than 1. Finally, in the study 4, in vitro analysis of the effect of poppers on BC-3 cells chronically infected by HHV-8 has been shown to stimulate viral replication. This result suggests that poppers used in vivo could be an environmental factor favoring the transmission of HHV-8 but also the development of MK in patients with apparent normal or restored immunity